Cargando…

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases

Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to an...

Descripción completa

Detalles Bibliográficos
Autores principales: MUTO, Yusuke, KAMBAYASHI, Yumi, KATO, Hiroshi, FUKUSHIMA, Satoshi, ITO, Takamichi, MAEKAWA, Takeo, FUJISAWA, Yasuhiro, YOSHINO, Koji, UCHI, Hiroshi, MATSUSHITA, Shigeto, YAMAMOTO, Yuki, AMAGAI, Ryo, OHUCHI, Kentaro, HASHIMOTO, Akira, FUJIMURA, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631249/
https://www.ncbi.nlm.nih.gov/pubmed/35670329
http://dx.doi.org/10.2340/actadv.v102.678
_version_ 1784823776578371584
author MUTO, Yusuke
KAMBAYASHI, Yumi
KATO, Hiroshi
FUKUSHIMA, Satoshi
ITO, Takamichi
MAEKAWA, Takeo
FUJISAWA, Yasuhiro
YOSHINO, Koji
UCHI, Hiroshi
MATSUSHITA, Shigeto
YAMAMOTO, Yuki
AMAGAI, Ryo
OHUCHI, Kentaro
HASHIMOTO, Akira
FUJIMURA, Taku
author_facet MUTO, Yusuke
KAMBAYASHI, Yumi
KATO, Hiroshi
FUKUSHIMA, Satoshi
ITO, Takamichi
MAEKAWA, Takeo
FUJISAWA, Yasuhiro
YOSHINO, Koji
UCHI, Hiroshi
MATSUSHITA, Shigeto
YAMAMOTO, Yuki
AMAGAI, Ryo
OHUCHI, Kentaro
HASHIMOTO, Akira
FUJIMURA, Taku
author_sort MUTO, Yusuke
collection PubMed
description Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types.
format Online
Article
Text
id pubmed-9631249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-96312492022-11-17 Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases MUTO, Yusuke KAMBAYASHI, Yumi KATO, Hiroshi FUKUSHIMA, Satoshi ITO, Takamichi MAEKAWA, Takeo FUJISAWA, Yasuhiro YOSHINO, Koji UCHI, Hiroshi MATSUSHITA, Shigeto YAMAMOTO, Yuki AMAGAI, Ryo OHUCHI, Kentaro HASHIMOTO, Akira FUJIMURA, Taku Acta Derm Venereol Original Article Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types. Society for Publication of Acta Dermato-Venereologica 2022-08-11 /pmc/articles/PMC9631249/ /pubmed/35670329 http://dx.doi.org/10.2340/actadv.v102.678 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Original Article
MUTO, Yusuke
KAMBAYASHI, Yumi
KATO, Hiroshi
FUKUSHIMA, Satoshi
ITO, Takamichi
MAEKAWA, Takeo
FUJISAWA, Yasuhiro
YOSHINO, Koji
UCHI, Hiroshi
MATSUSHITA, Shigeto
YAMAMOTO, Yuki
AMAGAI, Ryo
OHUCHI, Kentaro
HASHIMOTO, Akira
FUJIMURA, Taku
Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title_full Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title_fullStr Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title_full_unstemmed Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title_short Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
title_sort adjuvant anti-pd-1 antibody therapy for advanced melanoma: a multicentre study of 78 japanese cases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631249/
https://www.ncbi.nlm.nih.gov/pubmed/35670329
http://dx.doi.org/10.2340/actadv.v102.678
work_keys_str_mv AT mutoyusuke adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT kambayashiyumi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT katohiroshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT fukushimasatoshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT itotakamichi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT maekawatakeo adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT fujisawayasuhiro adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT yoshinokoji adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT uchihiroshi adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT matsushitashigeto adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT yamamotoyuki adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT amagairyo adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT ohuchikentaro adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT hashimotoakira adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases
AT fujimurataku adjuvantantipd1antibodytherapyforadvancedmelanomaamulticentrestudyof78japanesecases